About Pelizaeus-Merzbacher Disease
Pelizaeus-Merzbacher disease (PMD) is an X-linked hypomyelinating leukodystrophy caused by mutations in PLP1, encoding proteolipid protein 1, a major component of myelin in the central nervous system. Inadequate or abnormal myelination causes progressive neurological impairment including nystagmus, hypotonia, ataxia, spasticity, and intellectual disability. The connatal form is most severe with onset at birth; the classic form presents in early infancy. There are no approved therapies; stem cell and gene therapy approaches are in active development.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Pelizaeus-Merzbacher Disease trials.
PLP1 mutation type (duplication, point mutation, deletion, null mutation) determines phenotype and is a critical eligibility factor for gene therapy trials
Brain MRI showing hypomyelination pattern is required for diagnostic confirmation and trial documentation
Allogeneic stem cell transplantation has been attempted in small studies — transplant status may affect future trial eligibility
PLP1 null mutations causing a distinct milder spastic paraplegia form (SPG2) may be excluded from PMD-specific trials
Patient Resources
Find recruiting Pelizaeus-Merzbacher Disease trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Pelizaeus-Merzbacher Disease. Updated daily.